Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:GEO
NYSE:GEOCommercial Services

GEO Group (GEO) Valuation After Record Contract Wins And CEO Transition

GEO Group (GEO) is back in focus after its biggest year of new and expanded government contracts, combined with a CEO transition that brings founder Dr. George Zoley back into the top job. See our latest analysis for GEO Group. The recent contract wins and CEO transition come after a mixed run in the share price, with a 1-day share price return of 5.49%, a 30-day share price return decline of 19.22%, a 1-year total shareholder return decline of 47.87%, and positive 3-year and 5-year total...
NYSE:FTI
NYSE:FTIEnergy Services

A Look At TechnipFMC (FTI) Valuation As Buybacks And Offshore Demand Attract Fresh Trading Interest

Why TechnipFMC is back on traders’ radar TechnipFMC (FTI) has jumped into focus after recent share buyback activity coincided with strong trading volume, tightening the spotlight on how offshore and subsea project demand could influence margins and short term price action. See our latest analysis for TechnipFMC. At a share price of $61.36, TechnipFMC has seen strong recent momentum, with a 30 day share price return of 17.64% and a 1 year total shareholder return above 100%. Traders appear to...
NasdaqGS:ALNY
NasdaqGS:ALNYBiotechs

Will First GAAP Profit Year and Amvuttra Expansion Shift Alnylam Pharmaceuticals' (ALNY) Narrative?

In February 2026, Alnylam Pharmaceuticals reported its fourth-quarter and full-year 2025 results, showing revenue rising to US$1.10 billion for the quarter and US$3.71 billion for the year, with a shift from prior losses to net income of US$111.54 million in Q4 and US$313.75 million for 2025. The company’s first full year of GAAP profitability was largely powered by Amvuttra’s expanded use in transthyretin amyloid cardiomyopathy and was accompanied by a US$2.26 billion shelf registration for...
TSE:2502
TSE:2502Beverage

Asahi’s Cyberattack Recovery And Mixed Segment Trends Might Change The Case For Investing In Asahi Group Holdings (TSE:2502)

Asahi Group Holdings disclosed that a cyberattack earlier in the fiscal year forced delays to its third-quarter and full-year 2025 results, but by March 10, 2026 it had restored enough systems to reschedule the third‑quarter announcement while leaving the full‑year date still to be confirmed. Alongside these reporting updates, January data showed softer domestic beer‑type beverage sales but growth in whiskey, spirits and food, highlighting how Asahi’s different business lines are absorbing...
NasdaqGM:DJT
NasdaqGM:DJTInteractive Media and Services

Trump Media’s Crypto Staking ETF Push Could Be A Game Changer For Trump Media (DJT)

In recent filings, Trump Media & Technology Group’s affiliate Truth Social Funds sought SEC approval for two crypto ETFs tied to Bitcoin, Ether, and Cronos that incorporate staking rewards, offered in partnership with Crypto.com and advised by Yorkville America Equities. This move extends Trump Media’s business beyond social media into crypto-linked investment vehicles, deepening its relationship with Crypto.com and broadening its exposure to digital-asset infrastructure. We’ll now examine...
NYSE:WHR
NYSE:WHRConsumer Durables

How Investors May Respond To Whirlpool (WHR) Expanding Into AI-Enabled Premium Kitchen And Laundry Appliances

Earlier this month, Whirlpool Corporation’s brands used the 2026 Kitchen and Bath Industry Show to unveil a wave of advanced smart appliances, including KitchenAid’s AI-enabled ovens and refrigerators, Whirlpool’s UV Clean laundry tower and nugget-ice refrigerators, and a Spearmint-themed Color of the Year range. This cluster of launches underlines Whirlpool’s push to differentiate through design and embedded intelligence, signaling a focus on higher-value, premium home appliances across its...
NYSE:KO
NYSE:KOBeverage

Is It Time To Reassess Coca-Cola (KO) After Strong Multi Year Share Price Gains

If you are wondering whether Coca-Cola is fairly priced at around US$78.68 or if the market is asking too much for such a well known brand, you are not alone. The stock has had a mixed short term patch, with a 0.4% decline over the last 7 days, but returns of 11.7% over 30 days, 13.8% year to date, 17.6% over 1 year, 43.2% over 3 years and 82.5% over 5 years give useful context for any valuation check. Recent coverage has continued to focus on Coca-Cola's role as a global consumer staples...
NYSE:MFA
NYSE:MFAMortgage REITs

Assessing MFA Financial (MFA) Valuation As Dividend Sustainability Concerns Intensify

Dividend strain moves to the forefront for MFA Financial (MFA) A recent review of MFA Financial’s dividend shows payouts at 180% of Q3 2025 earnings, with operating cash flow covering only 0.27 times dividends over the first nine months of 2025. See our latest analysis for MFA Financial. The recent dividend concerns sit alongside mixed price action, with a 90 day share price return of 8.68% and a 1 year total shareholder return of 7.81%. However, the 30 day share price return shows a 2.08%...
TSX:TFII
TSX:TFIITransportation

Assessing TFI International (TSX:TFII) Valuation As Earnings Expectations And Revenue Forecasts Are Cut

Why earnings expectations for TFI International (TSX:TFII) just shifted Wall Street analysts now expect TFI International (TSX:TFII) to post quarterly earnings of $0.85 per share and revenue of $1.92b, with both figures projected below the same quarter last year. See our latest analysis for TFI International. The recent reassessment of earnings expectations comes as TFI International’s share price sits at CA$163.62, with a 90 day share price return of 38.06% but a 1 year total shareholder...
NasdaqGS:SFM
NasdaqGS:SFMConsumer Retailing

Is Sprouts Farmers Market (SFM) Pricing Look Attractive After Recent Share Price Pullback

If you are wondering whether Sprouts Farmers Market at around US$68.96 is starting to look expensive or still offers value, this article will walk through what the numbers are actually saying. The stock has been volatile recently, with a 2.4% gain over the last 7 days, a 12.3% decline over 30 days, and a 14.5% decline year to date, after a 61.1% decline over the last year, even though the 3 year and 5 year returns sit at 108.7% and 215.2% respectively. These swings have kept Sprouts Farmers...
NasdaqGM:SUPN
NasdaqGM:SUPNPharmaceuticals

Is Supernus Pharmaceuticals (SUPN) Still Attractive After A 30% One Year Share Price Gain

If you are wondering whether Supernus Pharmaceuticals at around US$50.84 is still offering value or starting to look fully priced, you are in the right place. The stock has seen mixed short term moves, with a 1.6% decline over the last 7 days, a 1.7% gain over 30 days, and a 2.8% return year to date, while the 1 year return sits at 30.0% and the 5 year return at 71.7%. Recent attention on Supernus Pharmaceuticals has focused on how the market is reassessing specialty pharma names and their...
NYSE:RVLV
NYSE:RVLVSpecialty Retail

Revolve Flagship At The Grove Tests Offline Bet And Investor Nerves

Revolve Group (NYSE:RVLV) has opened a flagship store at The Grove in Los Angeles. The new location brings the REVOLVE and FWRD brands into a single, high profile physical space. This marks an expansion of the company’s offline footprint beyond its core online model. Revolve Group is stepping further into brick and mortar with a flagship store at The Grove, a move that puts its online native brands in front of heavy foot traffic. The stock closed at $25.09, with returns over the past year...
NasdaqGS:CVCO
NasdaqGS:CVCOConsumer Durables

Do Cavco Industries’ (CVCO) Insider Buys And Buybacks Clarify Its Long‑Term Capital Allocation Strategy?

In recent weeks, Cavco Industries announced that its CEO bought 1,000 shares for about US$495,000 while the company repurchased roughly US$44,000,000 of its stock, following a post-earnings pullback earlier this year. This combination of insider buying and corporate buybacks has been interpreted by many investors as a clear signal of management’s conviction in the business. We’ll now examine how this renewed insider confidence, highlighted by the CEO’s recent purchase, may influence Cavco’s...
OM:NIBE B
OM:NIBE BBuilding

A Look At NIBE Industrier (OM:NIBE B) Valuation After Margin Recovery And New Dividend

Why NIBE Industrier’s latest results matter for shareholders NIBE Industrier (OM:NIBE B) has drawn fresh attention after its Q4 2025 results showed operating margins at 13.1%, solid full year growth, higher net income, and a newly announced annual dividend. See our latest analysis for NIBE Industrier. The Q4 update and dividend news have arrived alongside a strong 90 day share price return of 21.15% and a 1 month share price return of 7.59%. However, the 1 year total shareholder return of...
NYSE:WFC
NYSE:WFCBanks

A Look At Wells Fargo (WFC) Valuation After New Funding Moves And Earnings Beat

Preferred dividend event and what it means for Wells Fargo stock Wells Fargo (WFC) has just declared quarterly dividends on six series of preferred stock, a capital allocation move that sits alongside its recent funding programs and mixed shelf registration. For you as a common shareholder, these preferred dividends do not change the common dividend directly, but they do shape how Wells Fargo structures its overall capital stack and ongoing funding costs. See our latest analysis for Wells...
NYSE:MCO
NYSE:MCOCapital Markets

Assessing Moody’s (MCO) Valuation After Sector Jitters From S&P Global Guidance

Sector jitters hit Moody's ahead of earnings Moody's (MCO) shares dropped 5% after S&P Global issued disappointing guidance and missed 2026 estimates, prompting investors to reassess financial data providers just as Moody's prepares to report quarterly earnings. See our latest analysis for Moody's. At a share price of $426.44, Moody's has seen a 1 month share price return decline of 20.87% and a 1 year total shareholder return decline of 17.82%. However, the 3 and 5 year total shareholder...
NasdaqGS:VRTX
NasdaqGS:VRTXBiotechs

Vertex Expands Beyond Cystic Fibrosis With WuXi Autoimmune T Cell Pact

Vertex Pharmaceuticals (NasdaqGS:VRTX) has entered into an agreement with WuXi Biologics to develop a trispecific T-cell engager for B-cell mediated autoimmune diseases. The deal gives Vertex exclusive rights to develop and commercialize this preclinical therapy, expanding its pipeline beyond cystic fibrosis and gene therapies. Vertex, trading at $491.47, has seen its share price move by 2.8% over the past week and 11.4% over the past month, with a 3-year return of 67.4% and a 5-year return...
SGX:JYEU
SGX:JYEURetail REITs

Lendlease Global Commercial REIT (SGX:JYEU) One Off Gain Fuels Earnings Narrative Debate

Lendlease Global Commercial REIT (SGX:JYEU) has just put out its H1 2026 scorecard, with recent half year numbers showing total revenue of S$102.8 million and basic EPS of S$0.0133 in H2 2025, alongside net income of S$32.4 million. The trust has seen revenue move from S$100.8 million in H2 2024 to around S$102.8 million in H2 2025, while basic EPS shifted from S$0.0158 to S$0.0133 over the same period. This gives investors a clearer view of how the income line and per unit figures have...